Dear Doctor - Participate in the Survey on valproic acid "A new survey has found that the use of Valproic acid is on the rise among people with epilepsy. The survey, which was conducted by the Epilepsy Foundation, found that nearly a third of respondents said they had used Valproic acid in the past year to treat their seizures. This is up from just over a fifth in a previous survey. Valproic acid is an anticonvulsant medication that is commonly used to treat epilepsy. It can be taken as a pill or liquid, and it works by reducing seizure activity in the brain. The medication is generally considered to be safe and effective, but there are some potential side effects, including drowsiness, nausea, vomiting, and weight gain.If you have epilepsy and are considering using Valproic acid to treat your seizures, talk to your doctor to see if it is the right option for you. Participate now."
1.
Retired Olympic athletes at greater risk of skin cancer and osteoarthritis, research reveals
2.
Three Cycles of Chemo Noninferior to Six for Rare Childhood Eye Cancer
3.
Celebrity Cancers Stoking Fear? Cisplatin Shortage Ends; Setback for Anti-TIGIT
4.
Year in Review: Non-Small Cell Lung Cancer
5.
Electronic Sepsis Alerts; Reducing Plaques in Coronary Arteries
1.
What Is Carboxyhemoglobin And How Can It Affect Your Health?
2.
Introducing the Corrected Calcium Calculator: A Revolutionary Tool in Medical Assessment
3.
Integrating Immunotherapy and Staging Guidelines in Lung Cancer Treatment
4.
The Technological Revolution in Precision Oncology and Tumor Microenvironment Therapy
5.
The Importance of Having a Quick and Effective Heparin Antidote
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
2.
Navigating the Complexities of Ph Negative ALL - Part XVI
3.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
4.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
5.
Efficient Management of First line ALK-rearranged NSCLC - Part VII
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation